Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
1st May 2005
National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]
Summary,
GUIDELINE OBJECTIVE(S)
To examine the clinical effectiveness and cost-effectiveness of intravenous formulations of topotecan monotherapy, pegylated liposomal doxorubicin hydorocholoride (PLDH) monotherapy, and paclitaxel used alone or in combination with a platinum-based compound for the second-line or subsequent treatment of advanced ovarian cancer
TARGET POPULATION
Women with relapsed advanced ovarian cancer
INTERVENTIONS AND PRACTICES CONSIDERED
National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]
Summary,
GUIDELINE OBJECTIVE(S)To examine the clinical effectiveness and cost-effectiveness of intravenous formulations of topotecan monotherapy, pegylated liposomal doxorubicin hydorocholoride (PLDH) monotherapy, and paclitaxel used alone or in combination with a platinum-based compound for the second-line or subsequent treatment of advanced ovarian cancer
TARGET POPULATION
Women with relapsed advanced ovarian cancer
INTERVENTIONS AND PRACTICES CONSIDERED
- Paclitaxel
- Pegylated liposomal doxorubicin hydrochloride (PLDH)
- Topotecan
- Clinical effectiveness
- Overall survival
- Progression-free survival
- Response (including complete and partial response)
- Quality of life
- Adverse effects of treatment
- Cost-effectiveness
- 11 September 2010
